Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

•Mutations in HUWE1, a ubiquitin ligase degrading oncogenes including c-MYC, are detected in over 30% of cervical cancer.•HUWE1 deficient tumors are highly proliferative and hampered in vitro/in vivo by GS-626510, a novel bromodomain inhibitor.•Clinical studies with BET inhibitors in cervical cancer patients harboring HUWE1/c-MYC gene derangements are warranted.